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Abstract
Introduction: Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is licensed for the treatment of
hepatocellular carcinoma. Rash is one of the most common side effects of its use, generally appearing within days
to a few weeks of commencing treatment. We report the first case of rash appearing nine months after starting
treatment with sorafenib.
Case presentation: A 75-year-old Caucasian man initially presented with asymptomatic transient jaundice. He was
diagnosed with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma after extensive investigation. He
tolerated sorafenib 400 mg twice a day before presenting nine months later with a rash, confirmed to be drug-
induced.
Conclusions: Sorafenib is a drug of choice in Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. It can
cause protracted rash quite late into treatment. Successful management of the rash could contribute to achieving
stable disease in hepatocellular carcinoma over a significant period of time.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most com-
mon neoplasm in the world and the third most frequent
cause of cancer death worldwide [1]. The incidence of
HCC is 500,000 to one million cases per year.
HCC is closely associated with hepatic cirrhosis in the
western world, being found in about 70% of all cases.
Treatment of HCC is effective in improving survival
only when diagnosed at an early stage of the disease.
Tumor staging at diagnosis is essential in deciding
appropriate treatment. The most recognized staging sys-
tems for HCC currently include the (i) Okuda staging
system, (ii) Cancer of the Liver Italian Program (CLIP)
scoring system and the (iii) Barcelona Clinic Liver Can-
cer (BCLC) staging (Tables 1 and 2) [2].
Using the BCLC staging stage A can be managed with
radical therapies, such as resection, transplantation or
percutaneous treatments. Stages B and C are managed
with new agents in clinical trials or palliative care.
Transarterial chemoembolization (TACE) is beneficial
but is limited by patient suitability and maximum dose
of chemotherapy agent used [3,4]. Stage D is for symp-
tomatic treatment [5].
Sorafenib is an oral multitargeted tyrosine kinase inhi-
bitor. It inhibits the receptor tyrosine receptors (RTKs),
VEGFR 1-3 (vascular endothelial growth factor recep-
tor), FLT-3 (fms-like tyrosine kinase receptor-3),
PDGFR (platelet-derived growth factor receptor ) and
the non-receptor serine threonine kinases BRAF (B-Raf
proto-oncogene serine/threonine-protein kinase) and
(C-Raf proto-oncogene serine/threonine-protein kinase)
CRAF. The BRAF and CRAF kinases are members of
the RAF/(mitogen-activated protein kinase) MEK/(extra-
cellular-signal-regulated kinases) ERK signaling cascade,
which is involved in the survival and proliferation of
tumor cells and is a therapeutic target in cancer [3-16].
Phase I trials of sorafenib demonstrated, in addition to
safety, promising efficacy in HCC. It was well tolerated;
most adverse events were mild to moderate in severity,
with most reported side effects at any grade being fatigue
(40%), anorexia (35%), diarrhea (34%), rash/desquamation
(27%) and hand-foot skin reaction (25%) [4,6,11].
Phase II trials evaluated efficacy and pharmacokinetics
of sorafenib in HCC and demonstrated anti-tumor activ-
ity in HCC. In one trial of 137 patients, 2.2% of patients
achieved a partial response and 33.6% had stable disease
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double blind, placebo-controlled trial (SHARP trial)
involving 602 patients with advanced HCC was con-
ducted. The median survival was 10.7 months in the
sorafenib group and 7.9 months in the placebo group
(P ≤ 0.001) [15].
Case presentation
A 75-year-old Caucasian man was referred for consid-
eration of systemic therapy after being diagnosed with
HCC. Prior to this diagnosis, he had been fit and well.
Past medical history was notable for type 2 diabetes
mellitus diagnosed a year earlier, for which he took met-
formin. He initially presented jaundiced, which cleared
spontaneously. Endoscopic retrograde cholangiopancrea-
togram (ECRP) was normal. Computed tomography
(CT) scan (Figure 1A-C) demonstrated three large liver
lesions, with the largest measuring under 5 cm in dia-
meter, biopsy of which confirmed HCC.
He was well with performance status (PS) 0, and a
Child-Pugh score A, AFP (alpha-fetoprotein) 604 ku-L.
His BCLC staging was B (Intermediate). A study of sora-
fenib versus placebo was discussed with our patient and
he was entered into the trial in September 2005. He was
started on a trial medication at a dose of 400 mg twice
a day. The initial side effect experienced was grade I
diarrhea managed with loperamide. CT scans a month
into treatment demonstrated stable disease. Our patient
was reviewed monthly. He remained well with stable
disease. Nine months after commencing therapy he pre-
sented with a rash. This was initially a dry scaly, itchy
rash, showing signs of early lichenification, mainly over
the lower half of the abdomen (Figure 2). It gradually
spread from the trunk to the arms within six weeks, and
became pustular. Topical emollients were commenced
with onset of the rash but their effect remained moder-
ate after four months. At this point the rash flared up
with some multiple ulcerations over the trunk and arms
(Figure 3).
He was reviewed by a dermatologist and a working
diagnosis of eczematous drug reaction was made. Biop-
sies were taken and the histology was reported as being
in keeping with a drug reaction (Figure 4). Our patient
was prescribed Fucibet cream (containing betametha-
sone 0.1%, fucidic acid 2%) to be applied twice daily for
a week. The rash improved on subsequent reviews.
Fourteen months after commencing treatment
(November 2006) our patient presented with a further
rash of common toxicity criteria (CTC) grade 2 over his
trunk and limbs. Study medication was stopped at that
point. Four weeks later the rash had resolved so the trial
medication was recommenced at a reduced dose of 400
mg daily. Our patient remained stable on monthly
reviews. Four months later he developed a similar rash
as previously; pruritic, mainly on the trunk, but worse
on the back. Dermovate (clobetasol propionate 0.05%),
diprobase creams and Piriton (chlorphenamine) pro-
vided little relief so the trial drug was suspended.
Within two months the rash resolved but our patient
was not recommenced on trial medication. In spite of
that, he again presented a new rash two months later
(four months after stopping trial medication). A derma-
tologist suspected nodular prurigo. Biopsies were taken
of the new rash. Histological findings were consistent
Table 1 The BCLC staging
Tumor Status
BCLC Stage PS Tumor Stage Okuda Stage Liver function
Stage A: early
A1 0 Single, <5 cm I No portal HT, normal bilirubin
A2 0 Single, <5 cm I Portal HT, normal bilirubin
A3 0 Single, <5 cm I Portal HT, normal bilirubin
A4 0 3 tumors, <3 cm I-II Child-Pugh A-B
Stage B
Intermediate HCC 0 Large multinodular I-II Child-Pugh A-B
Stage C: advanced 1-2 Vascular invasion/extrahepatic spread I-II Child-Pugh A-B
Stage D: end stage 3-4 Any III Child-Pugh C
Table 2 Okuda Staging System
POINTS
01
Tumor size <50% liver >50% liver
Ascites No Yes
Albumin (g/dL) ≥3< 3
Bilirubin (mg/dL) <3 ≥3
Okuda Stage Points
I0
II 1-2
III 3-4
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Page 2 of 6with nodular prurigo. This was managed with 1%
menthol in aqueous cream and 1:4 betnovate ointments
and the rash improved to CTC grade 1.
On the 2
nd August 2007 our patient agreed to resume
treatment with sorafenib at a dose of 400 mg on alter-
nate days. The rash continued to improve and comple-
tely resolved by 30
th June 2008 (Figure 5). His latest CT
s c a n sa tt h a tt i m e( F i g u r e6 A - C )c o n t i n u e dt os h o w
stable disease, almost three years after commencing
treatment.
Discussion
Sorafenib (Nexavar, Bayer) is a molecular inhibitor of
several tyrosine kinases. It targets the Raf/Mek/Erk path-
way [3-16]. Its efficacy has been demonstrated in clinical
trials [4,6,7,11,16]. Dermatological side effects including
rash/desquamation (27%), hand-foot skin reaction
(HFSR, 27%), pruritus (18%) and dry skin (10%) are well
documented. Other side effects include fatigue (40%),
anorexia (35%), diarrhea (40%) hypertension and ele-
vated amylase.
Figure 1 (A-C) CT scans (May 2005): HCC lesions in segment 7, caudate lobe, segment 5 of liver, respectively.
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commencing sorafenib [8-11,17]. The mechanism of the
rash is poorly understood. There appears to be a rela-
tionship between the eccrine activity of the skin, result-
ing in higher drug concentration in the areas of the rash
or desquamation [8]. Inhibition of HER-1/EGFR in the
skin is also thought to play a role in the development of
the rash [10]. Some studies found a relationship between
the Child-Pugh score prior to commencement of medi-
cation and the severity of the adverse drug reaction [4].
Figure 2 Drug reaction: rash on trunk.
Figure 3 Drug reaction: rash on trunk.
Figure 4 Histology of skin rash: drug reaction.
Figure 5 The course of our patient’s rash over time. (A)
Commenced sorafenib 400 mg BiD po. (B) First presentation of rash.
(C) Pustular rash with ulceration. (D) Resolution of rash with fucibet
cream. (E) Rash flare-up, sorafenib stopped. (F) Rash resolved,
sorafenib recommenced at 400 mg qd. (G) Rash recurrence. (H)
Sorafenib stopped. (I) Rash resolved, sorafenib NOT recommenced.
(J) New rash (nodular prurigo).
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Page 4 of 6The late presentation of the rash in our patient
appears to be the first reported of its kind in the litera-
ture to date. It first appeared nine months into treat-
ment; it was mild to moderate in severity but was
protracted and recurring. Management included moist-
urizing creams and topical steroids, the latter being of
limited use [10]. Further improvements in our under-
standing of the pathogenesis underlying the side effects
are needed in the management of these patients.
Unanswered questions regarding the protracted nature
of the rash in our patient include whether the relatively
long period the drug was tolerated prior to onset of the
rash, might have contributed to its persistence four
months after stopping the drug. Nodular prurigo, which
could arise as a result of long-term scratching of the
skin to any itchy stimulus, was confirmed in our patient
by the second biopsy (Figure 7) as a consequence of the
persistence of the original itchy rash. Reintroduction of
the drug at a reduced dose after resolution of the rash
did not precipitate recurrence. Our patient remained
stable at this dose of medication by July 2008.
Conclusions
Sorafenib, a multitargeted tyrosine kinase inhibitor, is a
drug of choice in patients with BCLC stage B HCC.
Skin rash is a common adverse drug reaction, occurring
Figure 6 (A-C) CT scans (January 2008): HCC lesions in caudate lobe, segment 7 and segment 5 of liver, respectively.
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Page 5 of 6within weeks of commencement of the drug. It is, how-
ever, important to note that the rash can present quite
late into treatment. Prompt recognition and manage-
ment of the rash remains vital to patients’ outcome.
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Figure 7 Histology of skin rash: nodular prurigo.
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